High Glycemic variability and fasting blood sugar increases mortality risk in diabetes patients

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-08-20 04:30 GMT   |   Update On 2022-08-20 05:59 GMT

China: A new study suggests that it is crucial to achieve normal and stable glucose levels concurrently since the presence of high glycemic variability and high glucose levels may aggravate the independent risk of premature death in type 2 diabetes patients. The findings of this study were published in Diabetes, Obesity, and Metabolism.The prevalence of type 2 diabetes has increased at...

Login or Register to read the full article

China: A new study suggests that it is crucial to achieve normal and stable glucose levels concurrently since the presence of high glycemic variability and high glucose levels may aggravate the independent risk of premature death in type 2 diabetes patients. The findings of this study were published in Diabetes, Obesity, and Metabolism.

The prevalence of type 2 diabetes has increased at an unprecedented rate due to the growth in obesity and energy-dense diets, which is one of the main causes of premature death. According to researchers, there were 462 million cases of this illness worldwide in 2017, with a projected increase to 7079 cases per 100,000 people by 2030. Yahang Liu and colleagues thus carried out this research. to evaluate the individual and combined effects of mean fasting blood glucose level (M-FBG) and visit-to-visit fasting blood glucose variability (VVV-FBG) on all-cause mortality.

There were 48 843 Chinese individuals with type 2 diabetes in this prospective cohort research. To assess the relationship between VVV-FBG and M-FBG and all-cause mortality, hazard ratios (HRs) and 95% confidence intervals (CIs) were computed using Cox proportional hazards regression models. Restricted cubic splines were used to analyze possible nonlinear connections, and relative excess risk owing to interaction was used to assess additive interaction (RERI). To evaluate the combined impacts of VVV-FBG and M-FBG, Cox generalized additive models (CGAMs) and bivariate response surface models were also applied.

The key findings of this study:

1. A mean follow-up of 6.99 years resulted in the observation of 4087 fatalities overall.

2. Researchers found that patients with values at the 95th percentile of average real variability (ARV) and M-FBG had an elevated risk of premature mortality of 23% and 38%, respectively, compared to patients with values at the 5th percentile of ARV and M-FBG.

3. On both an additive and a multiplicative scale, there was a significant interaction between glycemic variability (ARV) and M-FBG.

4. In comparison to low VVV-FBG and low M-FBG, high VVV-FBG and high M-FBG were associated with the greatest risk of all-cause death.

5. The CGAMs demonstrated substantial synergistic interactions between M-FBG and glycemic variability.

In conclusion, the importance of reaching normal and stable glucose levels concurrently in the management of blood glucose is highlighted by the fact that FBG measurements taken during follow-up might give additional information regarding the potential risk of all-cause mortality.

Future research may be required to define the ideal range of blood glucose variation and to explore the possibility that lower average blood glucose levels and long-term glycemic fluctuation are linked to a lower risk of premature mortality.

Reference: 

Liu, Y., Xu, H., Li, J., Yang, Y., Zhang, J., Liu, X., Li, J., Yu, Y., & Qin, G. (2022). Separate and combined effect of visit‐to‐visit glycaemic variability and mean fasting blood glucose level on all‐cause mortality in patients with type 2 diabetes: A population‐based cohort study. In Diabetes, Obesity and Metabolism. Wiley. https://doi.org/10.1111/dom.14826


Tags:    
Article Source : Diabetes, Obesity and Metabolism

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News